Patents Examined by Ruth Sophia Arieti
  • Optimized RPE65 promoter and coding sequences
    Patent number: 11969478
    Abstract: The present invention relates to the prevention and/or treatment of retinal dystrophy in a patient, including Leber congenital amaurosis (LCA).
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: April 30, 2024
    Assignee: UCL BUSINESS LTD.
    Inventors: Alexander Smith, Robin Ali
  • Enhanced oligonucleotides for inhibiting RTEL1 expression
    Patent number: 11898145
    Abstract: The present disclosure provides antisense oligonucleotides targeting Regulator of telomere elongation helicase 1 (RTEL1). The disclosure also provides, enhanced antisense oligonucleotides targeting RTEL1 for use in treating and/or preventing a hepatitis B virus (HBV) infection. Also disclosed are pharmaceutical compositions and their use.
    Type: Grant
    Filed: February 1, 2022
    Date of Patent: February 13, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Erik Funder, Natascha Hruschka, Susanne Kammler, Erich Koller, Brian Leonard, Souphalone Luangsay, Susanne Mohr, Tobias Nilsson, Søren Ottosen, Lykke Pedersen, Søren V. Rasmussen, Steffen Schmidt, Sabine Sewing, Daniel Turley, Johanna Marie Walther
  • Small cell lung cancer therapeutic agent containing oligonucleotide
    Patent number: 11866705
    Abstract: Disclosed is an oligonucleotide or a pharmacologically acceptable salt thereof, wherein the oligonucleotide comprises at least one defined nucleoside structure, can bind to a human nSR100 gene and has human nSR100 expression inhibiting activity. The oligonucleotide has a length of 12 to 20 mer, and is complementary to a defined target region. Further, disclosed is an nSR100 gene expression inhibitor and a cancer therapeutic agent containing the oligonucleotide or the pharmacologically acceptable salt thereof. The cancer therapeutic agent is used for treatment of small cell lung cancer, prostate cancer, or breast cancer.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: January 9, 2024
    Assignees: Osaka Univerity, National Institutes of Biomedical Innovation, Health and Nutrition, Luxna Biotech Co., Ltd.
    Inventors: Masahito Shimojo, Satoshi Obika, Yuya Kasahara, Takao Suzuki, Masaki Yamagami, Tadashi Umemoto
  • Systems, methods, and compounds for providing chaperone activity to proteins
    Patent number: 11780896
    Abstract: Systems and method for providing chaperone activity to a protein-containing compound is disclosed. The method includes selecting a nucleic acid based on one or more of the nucleic acid's particular properties and a specific sequence of the nucleic acid and applying the nucleic acid to a compound comprising one or more proteins to provide chaperone activity to the compound.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: October 10, 2023
    Assignee: University of Denver
    Inventors: Scott Horowitz, Adam Begeman, Ahhyun Son, Alexa Gomez, Theodore Litberg